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Abstract
Neonatal apnea is commonly treated by methylxanthines like caffeine or theophylline,
but these drugs have the potential to create serious side effects. As an alternative, a new xanthine
analog, 1-propylxanthine (1-PX), was recently synthesized at Eastern Illinois University. The
respiratory effects of 1-PX were investigated in 4- to 7-day-old rats to determine if 1-PX could
be a respiratory stimulant. Each rat was placed in a heated body plethysmograph, and its
respiratory rate and volume were measured using a flow transducer, pneumotachograph, and
Power Lab data acquisition system. After a 10-min control period, the rat was given a s.c. dose
of 1-PX (10, 20, 40, or 80 mg/kg) or saline. Respiration was then recorded for one hour. Doserelated increases were observed in respiratory rate and minute ventilation, while there were
highly variable changes in tidal volume and a small increase in mean inspiratory flow. The 80
mg/kg dose elicited a 32% increase in respiratory rate and an 8% increase in minute ventilation.
A CO2-response study was also conducted on a separate group of rats in order to determine if 1PX increases the respiratory response to CO2. In the CO2-response study, each rat (4- to 7-daysold) was placed in a heated body plethysmograph, and its respiratory rate and volume along with
the inspired CO2 concentration were recorded by a flow transducer, pneumotachograph, Datex252 airway gas monitor, and PowerLab data acquisition system. Respiration was recorded for 10
minutes while the rat was breathing room air (0% CO2). The CO2 concentration was then
increased in 1% increments from 1-6%. After the initial CO2-response test, each rat received a
s.c. injection of 20, 40, or 80 mg/kg 1-PX or saline. The CO2-response test was repeated at three
15-min intervals after drug administration. Dose-related increases were observed in both minute
ventilation and tidal volume, while there were highly variable changes in respiratory rate and
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mean inspiratory flow. The 80 mg/kg 1-PX dose elicited a 127% increase in minute ventilation
and an 84% increase in tidal volume. The results indicate that 1-PX is slightly less potent than
theophylline and approximately equal in potency to 1-methylxanthine as a respiratory stimulant.

Introduction
Pauses in breathing lasting from 6 to 10 seconds occur in all infants. These pauses are
due to the immaturity of the respiratory system and are not necessarily harmful to the infant (1).
If these pauses in breathing occur three or more times for more than three seconds with less than
20 seconds in respiration between pauses, the condition is termed apnea (1). Apnea is not
significant until the respiratory pauses last 20 seconds or longer or is coupled with bradycardia,
cyanosis, or pallor (1). Apnea and the resultant combination of bradycardia and desaturation
often require the use of pharmacological intervention that can cause serious side effects (2).
Methylxanthines are respiratory stimulants administered to neonates with apnea and have
been shown to affect the child’s growth, neurological development, and behavior (3). In
therapeutic ranges, theophylline, a methylxanthine, can cause side effects that include nausea,
headache, diuresis, and occasionally cardiac arrhythmias and seizures (4). Theophylline
(1,3-dimethylxanthine) has also caused tachycardia, vomiting, diarrhea, and abdominal
distention at therapeutic concentrations (5). Caffeine, another methylxanthine, has also been
shown to cause tachycardia at therapeutic levels and to affect the central nervous system causing
nervousness or anxiety, restlessness, tremors, insomnia, and hyperesthesia (6).
Neonatal apnea is thought to be caused by adenosine accumulation in the brain caused by
the dephosphoylation of adenosine triphosphate (ATP) during hypoxia. Methylxanthines block
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this hypoxia-induced apnea, and their therapeutic effects have been suggested to be due to the
antagonistic action on adenosine receptors (7). Methylxanthines are the most common type of
drug used to combat recurrent apnea in neonates because of the stimulatory effect that it has on
the respiratory center. The most important therapeutic action of methylxanthines in children and
adults is their ability to relax bronchial smooth muscle in order to increase air flow in diseases
such as asthma (6). Methylxanthines also appear to cause an increased sensitivity of the
medullary respiratory centers to the presence of CO2 which increases the respiratory minute
volume in response to increased alveolar Pco2 (6).
The 1-position of alkylxanthines is thought to be essential for adenosine antagonism
while the 3-position of xanthines is essential for increased bronchodilation. Both the 1-position
and 3-position of alkylxanthines may increase toxic potency. The 7-position of xanthines
decreases bronchodilation and toxic potency (8). Caffeine and theophylline, the two most used
xanthines, both have methyl groups at the 1 and 3 positions while caffeine also has a methyl
group at the 7-position (6). Since the 7-position causes decreased bronchodilation and the 3position has been shown to only enhance stimulation of respiration, the 1-position remains to be
the cause of respiratory stimulation (9). In this experiment, the respiratory effects of the new
drug, 1-propylxanthine (1-PX), were observed in neonatal rats with the hypothesis that 1-PX
increases the ventilation and increases the respiratory response to CO2 in neonatal rats.

Materials and Methods
Setting up the equipment for the procedure began with connecting the Power Lab to the
ETH-255 Bridge/ Bio Amplifier with a BNC cable plugged into the channel 1 output of the
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amplifier to the front channel 1 input of the Power Lab unit. Channel 1 controls were set as
follows: Gain= X1, Low Pass= 50 Hz, and High Pass= DC. The power supply was then turned
on to the water bath, pneumotachograph, Power Lab, amplifier, and computer. The Validyne
model MC 1-3 pneumotachograph was attached to a Fleisch #0000 flow transducer and plugged
into channel 1 of the amplifier. The chart program with approved settings was opened on the
computer with channel 1 recording the flow, channel 2 recording the total volume, and channel 3
recording the number of breaths. The instruments were calibrated to eliminate drift in the volume
recording. The chart calibration included opening the Computed Input Column for channel 2 and
turning the channel 1 offset knob to zero. The drift was rechecked before each animal treatment.
The volume calibration was performed by filling a 20 ml syringe with exactly 20 ml of air and
inserting the syringe on the left end of the flow transducer that is connected to the
pneumotachograph. The reset button located on the chart calibration screen was clicked and the
20 ml of air from the syringe was plunged into the flow transducer within 5 seconds. The reading
on channel 2 should be 20 ml; if this was not the case, then the calibration was repeated. After
the equipment was calibrated, the Computed Input screen was exited.
A newborn rat was randomly selected from a litter for a treatment. The rat was no less
than 4 days old and no more than 7 days old. The rat’s mass, sex, age, and litter number were
recorded in an Excel spreadsheet. An appropriate diaphragm with a hole in the center was
selected according to the size of the rat and was placed over the lubricated end of the
plethysmograph with a small rubber band. The rat’s head was forced through the hole in the
diaphragm, and a plastic crosspiece was placed behind the rat to keep it from backing out. The
end of the plethysmograph was plugged with a rubber stopper that contained a rubber tube that
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would be attached to the flow transducer. Lubricant was applied around the neck of the rat to
assure a tight seal. A small plastic cylinder was placed around the rat’s head to allow the rat to
rest its chin, and this cylinder was held in place with tape. The plethysmograph was placed in the
center of a jacketed water bath and the plastic tube from the plethysmograph was attached to the
flow transducer of the pneumotachograph.
Recording was started and continued for ten minutes. After the initial ten minutes, two
control measurements were taken by highlighting a ten second region of the graph in channel 1.
The chart data was then copied and pasted into an Excel spreadsheet. The injection was prepared
by determining the dose of 1-PX or saline (10 mg/kg with a concentration of 2 mg/ml, 20 mg/kg
with a concentration of 4 mg/ml, 40 mg/kg with a concentration of 8 mg/ml, 80 mg/kg with a
concentration of 16 mg/ml, or 0.9% NaCl) required by multiplying the rat’s mass by 5
microliters/ gram. The 80 mg/kg 1-PX dose was derived from the 8 mg/ml solution by doubling
the amount of the 8 mg/ml solution because there were solubility problems with higher
concentrations of 1-PX. The 1-PX was synthesized by Dr. Howard Black and Aaron Lineberry of
the Eastern Illinois University Chemistry Department. The 100 µl syringe was completely filled,
the 26 gauge needle was attached, and the solution was pushed into the 26G needle until a drop
of solution was ejected. The syringe was then filled completely to the determined amount, and
the rat was injected under the scalp of the neck with a single subcutaneous dose of 1-PX (10, 20,
40, or 80 mg/kg) or saline (0.9% NaCl) without removing the rat from the plethysmograph.
The plethysmograph was placed back into the jacketed water bath and attached to the
right side of the flow transducer of the pneumotachograph. Recording was started immediately
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after injection and continued for 60 minutes with 10 second recordings highlighted and saved to
the Excel spreadsheet every 5 minutes. Eight rats were tested at each dose, with a total of 40 rats
used in the study.
The same procedure as above was followed in the 1-PX CO2-response study with only a
few differences. Again, 4- to 7-day-old rats were used in this experiment, but the treatments were
reduced to saline, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-PX. Setting up the equipment for the
procedure began with connecting the Power Lab to the ETH-255 Bridge/ Bio Amplifier with a
BNC cable plugged into the channel 1 output of the amplifier to the front channel 1 input of the
Power Lab unit. Channel 1 controls were set as follows: Gain= X1, Low Pass= 50 Hz, and High
Pass= DC. The power supply was then turned on to the water bath, pneumotachograph, Power
Lab, amplifier, Datex-252 airway gas monitor, and computer. The Datex-252 airway gas monitor
was plugged into channel 1 of the amplifier while the Validyne model MC 1-3
pneumotachograph was attached to a Fleisch #0000 flow transducer and plugged into channel 2
of the amplifier. The chart program with approved settings was opened on the computer with
channel 1 recording the flow, channel 2 recording the total volume, channel 3 recording the
number of breaths, and channel 4 recording the CO2 concentration. The instruments were
calibrated to eliminate drift in the volume recording. The chart calibration included opening the
Computed Input Column for channel 2 and turning the channel 1 offset knob to zero. The drift
was rechecked before each animal treatment. The volume calibration was performed by filling a
20 ml syringe with exactly 20 ml of air and inserting the syringe on the left end of the flow
transducer that is connected to the pneumotachograph. The reset button located on the chart
calibration screen was clicked and the 20 ml of air from the syringe was plunged into the
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flow transducer in about 5 seconds. The reading on channel 2 should be 20 ml; if this was not the
case, then the calibration was repeated. After the equipment was calibrated, the Computed Input
screen was exited.
A newborn rat (4-to 7-days-old) was randomly selected from a litter for a treatment. The
rat’s mass, sex, age, and litter number were recorded in an Excel spreadsheet. An appropriate
diaphragm with a hole in the center was selected according to the size of the rat and was placed
over the lubricated end of the plethysmograph with a small rubber band. The rat’s head was
forced through the hole in the diaphragm, and a plastic crosspiece was placed behind the rat to
keep it from backing out. The end of the plethysmograph was plugged with a rubber stopper that
contained both a rubber tube that would be attached to the pneumotachograph and a rubber tube
that was attached to the gas mixer, Anthoson. Lubricant was applied around the neck of the rat in
order to assure a tight seal. A small plastic cylinder was placed around the rat’s head to allow the
rat to rest its chin, and this cylinder was held in place with tape. The plethysmograph was placed
in the center of the jacketed water bath, and the plastic tube from the plethysmograph was
attached to the flow transducer of the pneumotachograph. A rubber stopper plugged the other
end of the jacketed water bath at the end closest to the rat’s head, and a thin tube was inserted
through this rubber stopper into the jacketed water bath from the Datex-252 airway gas monitor.
Recording was started and continued for ten minutes while the rat was breathing room air
(0% CO2). An air compressor generated this room air by sending room air to a gas mixer,
Anthoson, that sent air into the jacketed water bath. The CO2 concentration was then increased in
1% increments from 1 to 6% by mixing CO2 from a concentrated gas tank and room air from the
air compressor with the gas mixer, Anthoson. The Datex-252 airway gas monitor detected the
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carbon dioxide level in the jacketed water bath and sent the signal to the PowerLab data
acquisition system, which converted this signal into quantitative data.
After the initial CO2-response test, the injection was prepared by determining the dose of
1-PX (20 mg/kg with a concentration of 4 mg/ml, 40 mg/kg with a concentration of 8 mg/ml, or
80 mg/kg with a concentration of 16 mg/ml) or 0.9% saline placebo required by multiplying the
rat’s mass by 5 microliters/ gram. The 80 mg/kg 1-PX dose was derived from the 8 mg/ml
solution by doubling the amount of the 8 mg/ml solution because there were solubility problems
with higher concentrations of 1-PX. The 1-PX was synthesized by Dr. Howard Black and Aaron
Lineberry of the Eastern Illinois University Chemistry Department. The 100 µl or 150 µl syringe
was completely filled, the 26 gauge needle was attached, and the solution was pushed into the
26G needle until a drop of solution was ejected. The syringe was then filled completely to the
determined amount, and the rat was injected under the scalp with a single subcutaneous dose of
1-PX or saline without removing the rat from the plethysmograph.
The plethysmograph was placed back into the jacketed water bath and attached to the
right side of the flow transducer of the pneumotachograph. The CO2-response test was then
repeated at 15, 30, and 45 minutes after drug administration. Minute ventilation (VE), respiratory
rate (f), tidal volume (VT), and mean inspiratory flow (VT/TI) at the varying levels of inspired
CO2 concentrations were collected by the PowerLab.

Results
The rats given saline had an overall reduction in their mean percent change in f and VE
with time, while the rats given lower doses of 1-PX had a decrease in mean percent change in
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VE, but to a lesser extent than saline shown in Figure 1 and 2. There were dose-related increases
in both mean percent change in f and VE compared to saline during the first 30 minutes after
administration of 1-PX (Fig. 1, 2). The f was significantly higher than the saline controls in the
20, 40, and 80 mg/kg 1-PX doses (p <0.01). The rats given the 80 mg/kg dose of 1-PX had the
greatest increase in mean percent change in f and in VE as compared to the saline treatment. The
40 mg/kg 1-PX dose elicited a greater response in the rats’ mean percent change in f and VE than
the 20 mg/kg dose and the 10 mg/kg dose as compared to the saline dose. For example, at 30
minutes the saline treatment elicited a 13% decrease in f and a 23% decrease in VE, the 10 mg/kg
1-PX dose elicited a 7% decrease in f and a 13% decrease in VE, the 20 mg/kg 1-PX dose caused
a 15% increase in f (p <0.05) and a 15% decrease in VE, and the 40 mg/kg 1-PX dose caused an
11% increase in f (p <0.01) and a 10% decrease in VE, while the 80 mg/kg 1-PX dose elicited a
26% increase in f (p <0.01) and an 8% increase in VE.
Figure 3 shows that the mean percent change in VT for the 10 mg/kg dose of 1-PX
increased compared to the saline dose. Saline produced an 11% decrease in mean percent change
in VT at 20 minutes, while the 10 mg/kg dose of 1-PX elicited a 4% decrease in mean percent
change in VT at 20 minutes. The remaining doses of 20 mg/kg, 40 mg/kg, and 80 mg/kg 1-PX
showed a decreased mean percent change in VT as compared to saline with the 80 mg/kg dose of
1-PX causing the greatest decrease. The 20 mg/kg dose of 1-PX seems to decrease the mean
percent change in VT more than the 40 mg/kg dose. No discernable pattern was seen in mean
percent change of VT; therefore, there seems to be no correlation between dose and effects on
VT. Mean percent change in VT/TI increased to a small extent by 1-PX shown in Figure 4.
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The VE, VT, and VT/TI increase in neonatal rat respiration both in the saline control
treatment and in the 1-PX doses in response to CO2; however, the slopes of the 1-PX doses are
steeper than the pre-injection control slopes. The f remains unchanged in neonatal rats in
respiration response to CO2. Also, the pre- and post-injection CO2 response curves are very
similar for the saline rats.
Within the CO2-response study, both mean percent change in VE and mean percent
change in VT exhibited dose-related increases as seen in Figures 5-9. The effects of 1-PX on
mean percent change of VE were clearly dose-related at 15 minutes post-injection as illustrated in
Figure 5. The greatest increase in mean percent change in VE occurred 30 minutes post-injection;
however, in this case, the 20 mg/kg 1-PX dose produced a slightly greater increase than the 40
mg/kg 1-PX dose as depicted in Figures 6. At 15 minutes post-injection, 6% CO2 caused a 65%
increase in mean percent change in VE for the saline dose (compared to a 54% increase preinjection), a 70% increase for the 20 mg/kg 1-PX dose, 82% increase for the 40 mg/kg 1-PX
dose, and 100% increase for the 80 mg/kg dose, while the mean percent change in VE in response
to 6% CO2 30 minutes post-injection was 76% for the saline dose (compared to a 54% increase
pre-injection), a 99% increase for the 20 mg/kg 1-PX dose, a 90% increase for the 40 mg/kg 1PX dose, and a 127% increase for the 80 mg/kg 1-PX dose. Both Figures 6 and 7 depict doserelated effects in mean percent change in VE at 30 and 45 minutes post-injection except that the
20 mg/kg and 40 mg/kg 1-PX doses were reversed with the 20 mg/kg dose of 1-PX having a
greater increase in mean percent change in VE than the 40 mg/kg dose of 1-PX.
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The greatest dose-related effects in mean percent change of VT occurred at 30 minutes
post-injection while 15 minutes post-injection also showed dose-related effects but to a lesser
extent than 30 minutes post-injection as illustrated in Figures 8 and 9. Mean percent change in
VT 45 minutes post-injection showed no discernable pattern as seen in Figure 10. Mean percent
change in f at 15, 30, and 45 minutes post-injection also displayed no discernable pattern;
however, a flat response to CO2 was observed in the mean percent change in f, and this flat
response was not altered by the drug treatment as depicted in Figures 11-13. Mean percent
change in VT/TI at 30 and 45 minutes post-injection shows the 40 mg/kg 1-PX dose as the most
effective dose while the other doses as well as the mean percent change in VT/TI at 15 minutes
post-injection seems to illustrate no discernable pattern as shown in Figures 14-16.
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Fig. 1. Time (min) vs mean percent change in respiratory rate of 8 neonatal rats injected with
doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline.
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Fig. 2. Time (min) vs mean percent change in minute ventilation of 8 neonatal rats injected with
doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline.
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Fig. 3. Time (min) vs mean percent change in tidal volume of 8 neonatal rats injected with
doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline.
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Fig. 4. Time (min) vs mean percent change in mean inspiratory flow of 8 neonatal rats injected
with doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and
saline.
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Mean Percent Change in Minute Ventilation
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Fig. 5. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal
rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 6. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal
rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.

Hance 15

Mean Percent Change in Minute Ventilation

120
100
80
Pre-Injection
Saline
20 mg/kg
40 mg/kg
80 mg/kg

60
40
20
0
-20
0

1

2

3

4

5

6

7

Percent Inspired CO2

Fig. 7. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal
rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 8. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats 15
minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 9. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats 30
minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 10. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats
45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 11. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal
rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 12. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal
rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 13. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal
rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 14. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8
neonatal rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 15. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8
neonatal rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Fig. 16. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8
neonatal rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of
1-propylxanthine and saline.
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Discussion
The results demonstrate that 1-PX stimulates respiration in neonatal rats and increases the
ventilatory response to CO2. The response was dose-related, with the 80 mg/kg 1-PX dose
eliciting the greatest increase in mean percent change in f and VE. For f, the 20, 40, and 80 mg/kg
1-PX doses were all significantly different from saline. These results exhibit similarities to the
respiratory effects produced by 1-methylxanthine (1-MX) (10). Both 1-PX and 1-MX increase f
and VE without increasing VT. This study provides more supporting evidence that substitution in
the 1-position is essential for stimulation of respiration by xanthine analogs. Comparison with 1MX suggests that the potency as a respiratory stimulant is not affected by the size of the alkyl
group on the 1-position. A previous study indicated that 3-propylxanthine (enprofylline) did not
stimulate respiration at doses up to 40 mg/kg (9), providing further supporting evidence that the
1-position is essential for stimulation of respiration by xanthine analogs. The increase in mean
percent change in VE produced by 80 mg/kg 1-PX is equivalent to the increase produced by 20
mg/kg theophylline (1,3-dimethylxanthine) (10), results indicating that 1-PX is less potent than
theophylline.
Mean percent change in VE was unusually high at 30 minutes post-injection of the
highest dose of 1-PX. Five out of the 8 rats illustrated this jump in VE (a 4-day-old female, two
4-day-old males, a 6-day-old female, and a 7-day-old female). Also, a 6-day-old male had
increased VE, but not an extreme jump like the other 5 rats. Two samples (one from the 20 mg/kg
data and one from the 40 mg/kg data) were thrown out and repeated due to computer problems
and excessive rat movement. The effectiveness of 1-PX correlates with the dose and thus
supports the hypothesis that 1-PX stimulates respiration in neonatal rats.

Hance 21
The CO2-response results demonstrate that 1-PX stimulates respiration in neonatal rats
under hypercapnic conditions. A flat f response to CO2 was observed and was unchanged by 1PX doses. Several previous studies have also observed this blunted f response to CO2 in the
respiration of neonatal rats (11, 12). A similar flat f response to CO2 has been reported in
premature human infants (13), justifying the use of newborn rats as a model for premature
infants with breathing problems. The ventilatory response to CO2 was dose-related, with the 80
mg/kg 1-PX dose eliciting the greatest response in VE. A similar increase in the VE response to
CO2 has been observed in preterm infants receiving theophylline (5). The results from the CO2response curve also exhibit similarities between 1-PX and theophylline since both drugs
increased VE primarily by increasing VT (14). While 1-PX does not appear to be superior to
theophylline as a respiratory stimulant, the possibility that 1-PX has fewer side effects should be
explored.
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